4//SEC Filing
Schuler Education Foundation 4
Accession 0000908834-23-000047
CIK 0000811240other
Filed
May 25, 8:00 PM ET
Accepted
May 26, 1:13 PM ET
Size
28.6 KB
Accession
0000908834-23-000047
Insider Transaction Report
Form 4
BIOLASE, INCBIOL
Schuler Family Foundation
10% Owner
Transactions
- Sale
Common Stock
2020-06-10$0.55/sh−1,733,836$953,610→ 5,217,400 total - Sale
Common Stock
2020-11-30$0.30/sh−1,115,000$334,500→ 7,573,243 total - Purchase
Common Stock
2020-02-11$0.61/sh+1,307,931$797,838→ 10,936,444 total - Sale
Common Stock
2020-11-24$0.30/sh−71,100$21,330→ 8,891,300 total - Sale
Common Stock
2020-12-04$0.30/sh−1,200,000$360,000→ 6,373,243 total - Sale
Common Stock
2020-12-17$0.28/sh−572,671$160,348→ 5,709,997 total - Sale
Common Stock
2020-12-16$0.28/sh−90,575$25,361→ 6,282,668 total - Award
Series F Convertible Preferred Stock
2020-07-22+1,498→ 1,498 totalExercise: $0.40From: 2020-07-22→ Common Stock (3,745,000 underlying) - Award
Warrants
2020-07-22+3,745,000→ 3,745,000 totalExercise: $0.40From: 2020-07-22Exp: 2025-07-22→ Common Stock (3,745,000 underlying) - Sale
Common Stock
2020-06-08$0.55/sh−1,847,649$1,016,207→ 9,088,795 total - Sale
Common Stock
2020-06-09$0.54/sh−2,137,559$1,154,282→ 6,951,236 total - Conversion
Common Stock
2020-07-28$0.40/sh+3,745,000$1,498,000→ 8,962,400 total - Sale
Common Stock
2020-11-25$0.29/sh−203,057$58,887→ 8,688,243 total - Sale
Common Stock
2020-12-18$0.28/sh−187,774$52,577→ 5,522,223 total - Conversion
Series F Convertible Preferred Stock
2020-07-28−1,498→ 0 totalExercise: $0.40From: 2020-07-22→ Common Stock (3,745,000 underlying)
Footnotes (7)
- [F1]This late filing is due to inadvertent administrative error.
- [F2]The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5399 and $0.5643, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- [F3]The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5430 and $0.5601, inclusive.
- [F4]The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5485 and $0.5656, inclusive.
- [F5]In connection with a public offering by the Issuer, on July 22, 2020, the Reporting Person acquired (i) 1,498 shares of Series F Convertible Preferred Stock, each of which is convertible into 2,500 shares of Common Stock, for a total of up to 3,745,000 shares of Common Stock, and (ii) 3,745,000 Warrants, each of which is exercisable to purchase one share of Common Stock, for a total of up to 3,745,000 shares of Common Stock, for an aggregate purchase price of $1,500,000.
- [F6]Each share of Series F Convertible Preferred Stock is convertible at the Issuer's option at any time on or after July 22, 2021 or at the option of the Reporting Person at any time.
- [F7]On July 28, 2020, the Reporting Person converted 1,498 shares of Series F Convertible Preferred Stock into 3,745,000 shares of Common Stock.
Documents
Issuer
BIOLASE, INC
CIK 0000811240
Entity typeother
IncorporatedIL
Related Parties
1- filerCIK 0001512977
Filing Metadata
- Form type
- 4
- Filed
- May 25, 8:00 PM ET
- Accepted
- May 26, 1:13 PM ET
- Size
- 28.6 KB